Earnest Partners LLC lessened its stake in shares of Catalent Inc (NYSE:CTLT) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,535,751 shares of the company’s stock after selling 199 shares during the quarter. Catalent comprises approximately 1.2% of Earnest Partners LLC’s holdings, making the stock its 12th largest position. Earnest Partners LLC owned about 1.74% of Catalent worth $137,463,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Catalent by 2.8% during the 2nd quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock worth $775,615,000 after acquiring an additional 388,615 shares during the last quarter. RMB Capital Management LLC boosted its position in shares of Catalent by 2.9% in the 2nd quarter. RMB Capital Management LLC now owns 96,597 shares of the company’s stock worth $5,237,000 after purchasing an additional 2,696 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of Catalent in the 2nd quarter worth $210,000. Castleark Management LLC bought a new position in shares of Catalent in the 2nd quarter worth $11,395,000. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Catalent by 23.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 162,645 shares of the company’s stock worth $8,817,000 after purchasing an additional 30,422 shares during the last quarter.
In other Catalent news, Director Gregory T. Lucier bought 2,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were bought at an average cost of $51.64 per share, for a total transaction of $103,280.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Steven L. Fasman sold 4,053 shares of Catalent stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $54.04, for a total transaction of $219,024.12. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.03. The company had revenue of $725.70 million for the quarter, compared to analysts’ expectations of $719.20 million. Catalent had a net margin of 5.46% and a return on equity of 15.89%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 EPS. Equities research analysts expect that Catalent Inc will post 1.81 EPS for the current fiscal year.
Several analysts have issued reports on the company. Morgan Stanley lifted their price target on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, August 28th. Jefferies Financial Group upgraded Catalent from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $50.00 to $62.00 in a report on Friday, June 21st. UBS Group boosted their price objective on Catalent to $64.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Finally, Robert W. Baird boosted their price objective on shares of Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $57.14.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.